Stocks · News reference
Needham Adjusts Price Target on Globus Medical
Needham has lowered its price target for Globus Medical while maintaining a Buy rating on the stock.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BMO Capital Downgrades Globus Medical to Market Perform
BMO Capital has downgraded Globus Medical from Outperform to Market Perform, while simultaneously reducing its price target for the company's stock.
Globus Medical Reports Third Quarter 2026 Results and Announces Share Repurchase Program Increase
Globus Medical announced its third quarter 2026 financial results, reporting worldwide net sales of $763.7 million and a $500 million increase to its share repurchase program.
Globus Medical Completes Acquisition of Synaptive Medical
Globus Medical, Inc. announced the completion of its acquisition of Synaptive Medical, a company specializing in cranial neurosurgery technologies.
Waters Q3 Earnings & Revenues Beat Estimates, 2026 Guidance Raised
Waters Corporation delivered robust third-quarter 2026 results with adjusted EPS rising 21% to $4.10 and revenues surging 121% to $1.77 billion, driven by strong demand for analytical instruments and chemistry consumables. The company raised its 2026 revenue guidance to $6.479B-$6.497B and adjusted EPS guidance to $14.60-$14.70, while announcing the acquisition of MOBILion Systems to strengthen its proteomics market position.
BDX Gears Up to Report Q4 Results: How to Play the Stock?
Becton Dickinson (BDX) is set to report Q4 fiscal 2026 results on Nov. 5, with EPS expected to grow 2.53% despite a 13% revenue decline. While Medical Essentials and Interventional segments show strength, China market challenges and a 200-basis-point Alaris revenue headwind are expected to weigh on quarterly performance. The company has a positive Earnings ESP of +0.21% and Zacks Rank #2, suggesting an earnings beat is unlikely despite historical performance.